ArticleJournal of thoracic disease2018

Combination immuno-oncology therapy with pembrolizumab, an anti-PD-1 monoclonal antibody targeting immune evasion, and standard chemotherapy for patients with the squamous and non-squamous subtypes of non-small cell lung cancer.

Masaru KatohPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.